QMed, Inc. (QMED) Stock Analysis
DELISTED 2023
What happened to QMed, Inc. (QMED) stock?
QMed, Inc. (QMED) no longer trades on public markets. It was delisted in November 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
QMed, Inc. (QMED) trades at $0.000001. QMed, Inc. is a company with a history in disease management services. Currently, the company does not have significant operations. Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for QMED: QMED does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates QMED against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
QMED: this read rests on a single discipline (Legends Council) — the other council disciplines have no scored data yet.
How is this calculated? →QMed, Inc. (QMED) Healthcare & Pipeline Overview
QMed, Inc., based in Eatontown, New Jersey, previously focused on disease management services for health plans and the federal government. Founded in 1983, the company currently lacks significant operational activities, positioning it as a dormant entity within the healthcare sector with a market capitalization of $0.00B.
What Is the Investment Thesis for QMED?
QMed, Inc. presents a speculative investment opportunity due to its lack of current operations and a market capitalization of $0.00B. The company's beta of 0.30 suggests low volatility relative to the market. Any investment decision would hinge on potential future strategic initiatives or a restructuring plan. Key considerations include the company's ability to revitalize its operations, secure new business ventures, or leverage its existing assets. Given the limited available information and absence of ongoing business activities, QMed, Inc. carries substantial risk and uncertainty. Investors should carefully evaluate any potential catalysts for future growth and thoroughly assess the company's financial viability.
Based on FMP financials and quantitative analysis
QMED Key Highlights
Market capitalization of $0.00B indicates a micro-cap valuation.
- Beta of 0.30 suggests lower volatility compared to the broader market.
- Previously engaged in disease management services for health plans and the federal government.
- Currently lacks significant operational activities.
- Employee base of 28 suggests a small-scale operation.
Who Are QMED's Competitors?
QMED is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACIXF Acarix AB (publ) | $0.03 | +0.00% | $31.5M | 52 |
| TRXDW TransEnterix, Inc. | $0.15 | -11.76% | $40.1M | 53 |
| EBRCZ EBR Systems, Inc. | $0.21 | -11.02% | $134M | 45 |
| SI SHOULDER INNOVATIONS, INC. | $23.26 | +10.08% | $482M | 30 |
| AVNBF Avon Technologies Plc | $22.49 | +0.00% | $662M | 38 |
| EBOSY EBOS Group Limited | $26.00 | +0.00% | $1.33B | 42 |
| BMXXY bioMérieux S.A. | $8.56 | +7.81% | $10.1B | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are QMED's Key Strengths?
Historical experience in disease management.
- Established relationships with health plans and government agencies (potentially valuable).
- Low beta suggests lower volatility.
- Potential for restructuring or strategic pivot.
What Are QMED's Weaknesses?
Lack of current significant operations.
- Unclear strategic direction.
- Limited financial information available.
- Small employee base.
What Could Drive QMED Stock Higher?
Announcement of a new strategic direction or business plan.
- Potential acquisition offer from another company.
- Efforts to restructure operations and reduce costs.
- Exploration of new business opportunities in the healthcare sector.
What Are the Key Risks for QMED?
Failure to revitalize operations and generate revenue.
- Inability to secure funding for new ventures.
- Limited financial disclosure and transparency.
- Risk of delisting or dissolution.
- Competition from established healthcare providers and technology companies.
What Are the Growth Opportunities for QMED?
- Strategic Acquisition: QMed could be acquired by a larger healthcare organization seeking to expand its service offerings or intellectual property. The healthcare industry is consolidating, with larger players acquiring smaller companies to gain market share and technological capabilities. A potential acquisition could provide QMed shareholders with a return on investment, contingent on the acquisition price and terms. Timeline: Within the next 1-3 years.
- Restructuring and New Business Model: QMed could restructure its operations and adopt a new business model focused on emerging healthcare trends such as telehealth, remote patient monitoring, or personalized medicine. These areas are experiencing rapid growth and offer opportunities for companies to develop innovative solutions. Success would depend on QMed's ability to attract experienced management, secure funding, and develop competitive products or services. Timeline: Within the next 2-4 years.
- Partnerships and Collaborations: QMed could form strategic partnerships with other healthcare providers, technology companies, or research institutions to develop and commercialize new products or services. Collaboration can provide access to resources, expertise, and market channels. Successful partnerships would require clear objectives, defined roles, and effective communication. Timeline: Within the next 1-2 years.
- Government Contracts: QMed could pursue government contracts related to healthcare initiatives, such as disease prevention, health promotion, or chronic disease management. Government contracts can provide a stable source of revenue and opportunities to scale operations. Securing these contracts would require demonstrating expertise, meeting regulatory requirements, and submitting competitive bids. Timeline: Ongoing.
- Intellectual Property Licensing: If QMed possesses any valuable intellectual property related to its previous disease management services, it could license this technology to other companies. Licensing agreements can generate revenue without requiring significant operational investment. The value of the intellectual property would depend on its uniqueness, market demand, and patent protection. Timeline: Ongoing.
What Threats Does QMED Face?
- Competition from established healthcare providers and technology companies.
- Regulatory changes in the healthcare industry.
- Economic downturn affecting healthcare spending.
- Inability to secure funding for new ventures.
What Are QMED's Competitive Advantages?
- Historical experience in disease management services.
- Established relationships with health plans and government agencies (potentially transferable).
- Any proprietary technology or intellectual property developed during previous operations (if any).
What Does QMED Do?
QMed, Inc. was established in 1983 and is headquartered in Eatontown, New Jersey. Historically, the company provided disease management services, targeting health plans and the federal government. These services aimed to improve patient outcomes and reduce healthcare costs through coordinated care programs. However, QMed, Inc. presently does not have significant operations. This transition marks a substantial shift from its original business model, leaving the company's current strategic direction unclear. The company's past involvement in disease management reflects a focus on population health and chronic care, areas that remain relevant in the healthcare industry. QMed's evolution and current state suggest a potential restructuring or strategic pivot, though specific details remain undisclosed. The company's small employee base of 28 may indicate a limited scope of activity or a transitional phase.
What Products and Services Does QMED Offer?
- Historically provided disease management services.
- Targeted health plans and the federal government.
- Aimed to improve patient outcomes.
- Focused on reducing healthcare costs.
- Offered coordinated care programs.
- Currently lacks significant operational activities.
How Does QMED Make Money?
- Previously generated revenue through contracts with health plans and government agencies.
- Offered disease management programs to improve patient care and reduce costs.
- Business model is currently inactive due to lack of significant operations.
What Industry Does QMED Operate In?
QMed, Inc. previously operated within the medical specialties sector, providing disease management services. This sector focuses on improving patient outcomes and managing chronic conditions through specialized care programs. The healthcare industry is characterized by increasing demand for cost-effective and patient-centered solutions. Competitors in this space include companies like BUGVF (Buhrmann Varia Groep NV), GNRS (Greenrose Acquisition Corp), LHRP (LHA Racecourse Properties), RFCS (RFC Systems, Inc.), and ROIX (ROI Acquisition Corp II), which offer various healthcare services and technologies. QMed's current lack of operations positions it outside the active competitive landscape, pending any future strategic shifts.
Who Are QMED's Key Customers?
- Health plans.
- Federal government agencies.
- Patients enrolled in disease management programs.
QMED Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in QMed's future, indicating that key stakeholders believe in the company's growth potential.
- Community sentiment has shifted positively as discussions around innovative product pipelines have gained traction, reflecting optimism among traders.
- Analysts have highlighted recent partnerships that enhance QMed's market position, suggesting a strengthening competitive edge.
- The overall healthcare sector's resilience has bolstered interest in QMed, as investors seek stability in trusted companies amidst market volatility.
Bear Case
- Concerns over regulatory hurdles have surfaced, with discussions around potential delays impacting QMed's product launches, creating uncertainty.
- Social sentiment shows some skepticism about QMed's ability to scale operations effectively, with traders expressing doubts about management execution.
- Recent negative news cycles regarding the healthcare sector have dampened investor enthusiasm, leading to cautious sentiment surrounding QMed.
- Some community members have pointed to broader economic challenges that could hinder QMed's growth, emphasizing a cautious approach in the current market landscape.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
QMED Latest News
No recent news available for QMED.
Leadership: Jane Ann Murray
Managing
Jane Ann Murray serves as the managing person at QMed, Inc., overseeing a team of 28 employees. Information regarding her prior experience and educational background is not available. Her leadership is focused on guiding the company through its current phase, characterized by a lack of significant operations. Her role involves strategic decision-making and potential exploration of new business opportunities.
Track Record: Due to the company's current state of limited operations, it is difficult to assess Jane Ann Murray's track record in terms of key achievements or strategic decisions. Her primary focus appears to be on maintaining the company's infrastructure and exploring potential future directions. Specific milestones or accomplishments under her leadership are not publicly available.
QMED OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that QMed, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial reporting. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and oversight, resulting in higher risk for investors. This tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in QMED.
- Low trading volume and wide bid-ask spread can lead to price volatility.
- OTC Other tier status indicates a higher risk of fraud or mismanagement.
- Lack of significant operations raises concerns about the company's viability.
- The company's future is highly uncertain due to its current inactive state.
- Verify the company's legal standing and registration.
- Investigate the background and experience of the management team.
- Assess the company's financial condition and any outstanding liabilities.
- Determine the company's plans for future operations.
- Evaluate the potential risks and rewards of investing in QMED.
- Consult with a qualified financial advisor.
- Review any available financial statements or disclosures.
- Company has been in existence since 1983.
- Company is based in the United States.
- Company has a registered CEO.
- Company previously engaged in legitimate business activities (disease management).
What Investors Ask About QMed, Inc. (QMED) — Healthcare
What happened to QMed, Inc. (QMED) stock?
QMed, Inc. (QMED) no longer trades on public markets. It was delisted in November 2023. The figures below are historical and are not a current quote.
Can I still buy QMED shares?
No. QMED stopped trading on public markets in November 2023, so the shares are not available through a broker. Anything you see quoted for QMED elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before QMED stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to QMed, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does QMed, Inc. do?
QMed, Inc. historically provided disease management services to health plans and the federal government, focusing on improving patient outcomes and reducing healthcare costs through coordinated care programs. However, the company currently lacks significant operations, marking a substantial shift from its original business model. The company's future direction is uncertain, pending potential restructuring or strategic initiatives.
What do analysts say about QMED stock?
There is currently no analyst coverage for QMED stock due to the company's lack of significant operations and limited financial disclosure. Key valuation metrics are not applicable in the absence of revenue or earnings. Any investment decision would be highly speculative and based on potential future developments.
What are the main risks for QMED?
The main risks for QMED include the lack of current operations, limited financial disclosure, and the uncertainty surrounding its future strategic direction. The company's OTC Other tier status indicates a higher risk of fraud or mismanagement. Low trading volume and wide bid-ask spread can lead to price volatility. Investors should be aware of the potential for delisting or dissolution.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's lack of significant operations and limited financial disclosure.
- AI analysis is pending, which may provide additional insights.